About iMetabolic Biopharma
iMetabolic Biopharma is an early stage precision medicine biopharma company that is developing a therapeutic to treat obesity-related diseases. This includes a spectrum of disorders, but the company has elected to focus initially on hyperlipidemia in the form of Familial Chylomiconemia Syndrome.
Missing: iMetabolic Biopharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: iMetabolic Biopharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest iMetabolic Biopharma News
Dec 17, 2020
December 17, 2020 08:00 AM Eastern Standard Time TEMPE, Ariz.--( BUSINESS WIRE )--iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. In this new agreement, iMBP gains access to additional OmniAb species and technologies, enabling the acceleration of iMBP’s development of assets through its iPlatform™ Technology. This strengthened partnership’s goal is to allow iMBP to generate a robust pipeline of therapeutic candidate molecules with clinically desired results, improved targeting, greater precision, improved safety, at lower cost, and application to a broad range of indications and disease areas. These molecules provide a unique set of complex biological actions that we think can be selectively engineered to improve target pathogen binding, and to elicit specific biological function for enhanced efficacy, clearance and/or administration. iMBP’s iPlatform™ pipeline expansion is building upon the accelerating progress in development of its primary iMBP-001 asset. Dr. Urban A. Kiernan, iMBP’s founder and CEO, commented, “Ligand has been an outstanding strategic partner in fostering the growth and development of our company. The OmniAb antibody discovery platform has helped accelerate our discovery programs by streamlining both cost and time, thus leading to our program expansion and successful development of the iPlatform™.” “The iMetabolic pipeline molecules can be thought of, in essence, as gene therapy implemented purely at the protein level, and represent a strategy that we would be excited to see emerge as a clinically-viable modality,” said Bill Harriman, Ph. D., Senior Vice President of Antibody Discovery at Ligand Pharmaceuticals. “Leveraging multiple host species, the OmniAb platform is uniquely positioned to deliver antibodies to precise epitopes that will enable this approach.” About Ligand’s OmniAb® Antibody Discovery Technology Suite Ligand’s OmniAb technology suite includes a proprietary antigen production platform, transgenic animal platforms that leverage four species, and proprietary high throughput B cell screening platforms that together can be utilized to deliver best-in-class fully human antibody leads for an expanded range of therapeutic targets. OmniRat® animals represent the industry’s first human monoclonal antibody technology based on rats. Because they have a complete immune system with a diverse antibody repertoire, OmniRat animals generate antibodies with human idiotypes as effectively as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic® is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. OmniChicken® animals comprise the industry’s first human monoclonal antibody technology based on chickens, and are especially useful in generating antibodies to highly conserved or difficult targets as well as antibodies that bind to pan-mammalian epitopes. The OmniClic® platform also leverages the chicken host system, but is specifically developed to facilitate the generation of common light chain bispecific antibodies. The OmniTaur platform leverages unique structural features of cow antibodies to address complex therapeutic targets. All of the OmniAb animal platforms, OmniRat, OmniFlic, OmniMouse, OmniChicken, OmniClic and OmniTaur, use patented technology, have broad freedom to operate, produce highly diversified, fully human antibody repertoires that are optimized in vivo for low immunogenicity, reliable manufacturability, and high therapeutic efficacy. About iMetabolic Biopharma Corporation iMetabolic Biopharma Corporation (iMBP) is a platform biopharmaceutical company developing safe, effective, and affordable First-In-Class therapeutics using its cornerstone technology, the iPlatform™. Based in Tempe, AZ, iMBP has initiated its discovery program and is in the early stages of establishing its peptide modulated fusion protein drug pipeline. With an initial focus on metabolic and cardiometabolic indications, the iPlatform™ candidates can expand into a number of high-need disease areas with great precision that will achieve better, safer, and more cost-effective patient outcomes. For more information, please visit www.imbiopharma.com . Follow iMetabolic Biopharma Corporation on social media. Twitter: @iMetabiopharma
iMetabolic Biopharma Frequently Asked Questions (FAQ)
When was iMetabolic Biopharma founded?
iMetabolic Biopharma was founded in 2017.
Where is iMetabolic Biopharma's headquarters?
iMetabolic Biopharma's headquarters is located at Tempe.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.